DK3145517T3 - Funktionelle oligodendrocytter afledt fra pluripotente stamceller og fremgangsmåder til fremstilling og anvendelse deraf - Google Patents

Funktionelle oligodendrocytter afledt fra pluripotente stamceller og fremgangsmåder til fremstilling og anvendelse deraf Download PDF

Info

Publication number
DK3145517T3
DK3145517T3 DK15796034.5T DK15796034T DK3145517T3 DK 3145517 T3 DK3145517 T3 DK 3145517T3 DK 15796034 T DK15796034 T DK 15796034T DK 3145517 T3 DK3145517 T3 DK 3145517T3
Authority
DK
Denmark
Prior art keywords
oligodendrocyts
derived
functional
manufacture
methods
Prior art date
Application number
DK15796034.5T
Other languages
English (en)
Inventor
Valentina Fossati
Panagiotis Douvaras
Original Assignee
New York Stem Cell Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Stem Cell Found Inc filed Critical New York Stem Cell Found Inc
Application granted granted Critical
Publication of DK3145517T3 publication Critical patent/DK3145517T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
DK15796034.5T 2014-05-22 2015-05-22 Funktionelle oligodendrocytter afledt fra pluripotente stamceller og fremgangsmåder til fremstilling og anvendelse deraf DK3145517T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462002048P 2014-05-22 2014-05-22
PCT/US2015/032274 WO2015179822A1 (en) 2014-05-22 2015-05-22 Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same

Publications (1)

Publication Number Publication Date
DK3145517T3 true DK3145517T3 (da) 2020-11-30

Family

ID=54554868

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15796034.5T DK3145517T3 (da) 2014-05-22 2015-05-22 Funktionelle oligodendrocytter afledt fra pluripotente stamceller og fremgangsmåder til fremstilling og anvendelse deraf

Country Status (10)

Country Link
US (3) US10301592B2 (da)
EP (1) EP3145517B1 (da)
JP (2) JP6873705B2 (da)
KR (2) KR102324714B1 (da)
CN (1) CN106456672B (da)
AU (1) AU2015263951B2 (da)
DK (1) DK3145517T3 (da)
ES (1) ES2846860T3 (da)
PL (1) PL3145517T3 (da)
WO (1) WO2015179822A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3145517T3 (pl) * 2014-05-22 2021-04-06 New York Stem Cell Foundation, Inc. Funkcjonalne oligodendrocyty pochodzące z pluripotencjalnych komórek macierzystych oraz sposoby ich otrzymywania i stosowania
CN105567642B (zh) * 2016-02-01 2019-07-12 中国科学院生物物理研究所 一种着色性干皮病人多能干细胞的制备方法
EP3436567A4 (en) * 2016-03-30 2019-10-30 Asterias Biotherapeutics, Inc. OLIGODENDROCYTE PROGENITOR CELL COMPOSITIONS
WO2018191656A1 (en) * 2017-04-13 2018-10-18 The Board Of Trustees Of The Leland Stanford Junior University Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro
KR20200026984A (ko) * 2017-07-13 2020-03-11 알렐 바이오테크놀로지 앤 파마슈티칼스, 인크. 랜드마크 전사 인자를 사용한 줄기 세포 분화에 의한 신경 전구 세포, 핍지교세포 전구 세포, 및 핍지교세포의 유도
WO2019023793A1 (en) * 2017-08-04 2019-02-07 University Health Network GENERATION OF OLIGODENDROGENIC NEURON PROGENITOR CELLS
CA3006897A1 (en) * 2017-08-04 2019-02-04 University Health Network Generation of oligodendrogenic neural progenitor cells
CN107858331B (zh) * 2017-11-02 2021-01-15 北京全式金生物技术有限公司 一种诱导人多能性干细胞分化为脊髓运动神经前体细胞的方法
CN108384755A (zh) * 2018-02-08 2018-08-10 北京呈诺医学科技有限公司 一种高效、快捷的诱导性多能干细胞向神经干细胞分化的方法
US20210163888A1 (en) * 2018-04-17 2021-06-03 Case Western Reserve University Induction of myelinating oligodendrocytes in human cortical spheroids
CN108624560B (zh) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 一种分化培养基及少突胶质前体细胞的制备方法
WO2019241620A1 (en) * 2018-06-14 2019-12-19 Academia Sinica Method to generate induced oligodendrocyte-lineage cells and treatment using such cells
EP3660145A1 (en) * 2018-11-30 2020-06-03 Assistance Publique, Hopitaux De Paris Use of oligodendrocytes from oral neuroectodermal stem cells in the repair of the nervous system
CA3127213A1 (en) 2019-01-23 2020-07-30 Asterias Biotherapeutics, Inc. Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
WO2020243618A1 (en) * 2019-05-29 2020-12-03 New York Stem Cell Foundation, Inc. Functional astrocytes derived from pluripotent stem cells and methods of making and using the same
MX2021014681A (es) * 2019-05-31 2022-04-06 Harvard College Células progenitoras de oligodendrocitos inducidas por la caja hmg relacionada con sry 9.
KR20220068222A (ko) 2019-08-23 2022-05-25 사나 바이오테크놀로지, 인크. Cd24 발현 세포 및 이의 용도
JPWO2021045217A1 (da) 2019-09-06 2021-03-11
CN110716595A (zh) * 2019-09-11 2020-01-21 合肥众建翔新能源有限公司 一种基于新能源的养殖系统
US20230293593A1 (en) 2020-03-25 2023-09-21 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
WO2021235848A1 (ko) * 2020-05-20 2021-11-25 고려대학교 산학협력단 희소돌기아교세포로 분화가 특화된 신경줄기세포로부터 희소돌기아교세포를 포함하는 오가노이드의 제조방법, 상기 방법으로 제조된 오가노이드 및 이의 용도
IL300516A (en) 2020-08-13 2023-04-01 Sana Biotechnology Inc Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
KR102568532B1 (ko) * 2021-01-13 2023-08-18 건국대학교 산학협력단 3차원 배양을 통한 신경줄기세포 제조 방법
AU2022247250A1 (en) * 2021-03-30 2023-11-09 Trailhead Biosystems Inc. Methods and compositions for generating oligodendrocyte progenitor cells
AU2022283291A1 (en) 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
IL310089A (en) 2021-07-14 2024-03-01 Sana Biotechnology Inc Differential expression of Y-linked antigens in hypoimmunogenic cells
CN113564122B (zh) * 2021-08-05 2022-04-08 呈诺再生医学科技(珠海横琴新区)有限公司 人诱导性多能干细胞向少突胶质细胞分化的方法，试剂盒以及应用
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
CN113699117B (zh) * 2021-09-03 2023-06-30 呈诺再生医学科技(北京)有限公司 经基因改造的少突胶质祖细胞在多发性硬化症中的应用
CN114262686B (zh) * 2022-03-02 2022-06-24 深圳市夏同生物医药科技有限公司 一种少突胶质细胞的制备方法及应用
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
KR20230171226A (ko) * 2022-06-13 2023-12-20 고려대학교 산학협력단 키나아제 저해제를 유효성분으로 포함하는 탈수초성 질환 예방 또는 치료용 약학적 조성물
CN115322965B (zh) * 2022-08-19 2024-01-30 同济大学 一种体外获得后脑底板细胞的方法、成套培养基及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1567186A2 (en) * 2002-12-06 2005-08-31 Singapore General Hospital Pte. Ltd. Nogo, caspr, f3 and nb-3 useful in the treatment of injury and disease to the central nervous system
WO2008026198A2 (en) * 2006-08-28 2008-03-06 Yeda Research And Development Co. Ltd. Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
US8227247B2 (en) * 2007-12-20 2012-07-24 Wisconsin Alumni Research Foundation Method of generating myelinating oligodendrocytes
WO2015124725A1 (en) * 2014-02-21 2015-08-27 Johan Ericson Late born central nervous system cell types
PL3145517T3 (pl) 2014-05-22 2021-04-06 New York Stem Cell Foundation, Inc. Funkcjonalne oligodendrocyty pochodzące z pluripotencjalnych komórek macierzystych oraz sposoby ich otrzymywania i stosowania

Also Published As

Publication number Publication date
US10301592B2 (en) 2019-05-28
EP3145517A1 (en) 2017-03-29
KR20210138783A (ko) 2021-11-19
JP2017524340A (ja) 2017-08-31
CN106456672B (zh) 2020-03-13
AU2015263951B2 (en) 2020-07-02
KR20170005844A (ko) 2017-01-16
KR102585909B1 (ko) 2023-10-05
US20200399595A1 (en) 2020-12-24
AU2015263951A1 (en) 2016-12-01
US11814648B2 (en) 2023-11-14
CN106456672A (zh) 2017-02-22
EP3145517A4 (en) 2017-11-15
ES2846860T3 (es) 2021-07-29
US10676716B2 (en) 2020-06-09
JP7410903B2 (ja) 2024-01-10
PL3145517T3 (pl) 2021-04-06
WO2015179822A1 (en) 2015-11-26
US20170183627A1 (en) 2017-06-29
JP6873705B2 (ja) 2021-05-19
US20190256820A1 (en) 2019-08-22
EP3145517B1 (en) 2020-08-26
JP2021118718A (ja) 2021-08-12
KR102324714B1 (ko) 2021-11-11

Similar Documents

Publication Publication Date Title
DK3145517T3 (da) Funktionelle oligodendrocytter afledt fra pluripotente stamceller og fremgangsmåder til fremstilling og anvendelse deraf
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
HK1244841A1 (zh) 用於選擇性消除所關注細胞的方法和組合物
HK1232239A1 (zh) 細胞穿透肽及其製造和使用方法
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
IL250689A0 (en) Rearrangement of pluripotent stem cells
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3240785T3 (da) Småmolekylede hæmmere af laktasedehydrogenase og fremgangsmåder til brug deraf
DK3702443T3 (da) Sammensætninger og fremgangsmåder til opformering og dyrkning af epiteliale stamceller
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
IL263265A (en) Use of mesenchymal stem cells and their parts
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3586821T3 (da) Stamcellestimulerende sammensætninger og metoder
DK3220973T3 (da) Kunstigt lungesystem og fremgangsmåder til anvendelse deraf
DK3183201T3 (da) Spilsamling og fremgangsmåde til anvendelse
DK3120055T3 (da) Membran og fremgangsmåde til fremstilling deraf
DK3104960T3 (da) Reaktiv sammensætning baseret på natriumbicarbonat og fremgangsmåde til fremstilling deraf
ZA201708773B (en) Agent for promoting migration of pluripotent stem cells
DK3204037T3 (da) Sammensætninger og kits til enzymatisk debridering og fremgangsmåder til anvendelse deraf
DK2962746T3 (da) Hydrofile membraner og fremgangsmåde til fremstilling deraf
DK3258809T3 (da) Smykkeelement og fremgangsmåde til fremstilling heraf
DK3325612T3 (da) Fremgangsmåder og sammensætninger til stamcelletransplantation